174 related articles for article (PubMed ID: 31308681)
1. Urinary orosomucoid: a new marker of cardiovascular risk in psoriatic patients?
Németh B; Péter I; Boncz I; Jagicza A; Kiss I; Csergő Á; Kőszegi T; Kustán P; Horváth IG; Ajtay Z
Ther Clin Risk Manag; 2019; 15():831-837. PubMed ID: 31308681
[TBL] [Abstract][Full Text] [Related]
2. Urinary Orosomucoid A Potential Marker Of Inflammation In Psoriasis.
Kustán P; Kőszegi T; Miseta A; Péter I; Ajtay Z; Kiss I; Németh B
Int J Med Sci; 2018; 15(11):1113-1117. PubMed ID: 30123048
[No Abstract] [Full Text] [Related]
3. Evaluation of serum and urinary orsomucoid protein A in psoriatic patients and their relation to severity of disease.
Khalid HN; Abd El Gayed EM; Elrsool AMA; Bazid HAS
J Cosmet Dermatol; 2022 Mar; 21(3):1185-1192. PubMed ID: 33905172
[TBL] [Abstract][Full Text] [Related]
4. Monitoring urinary orosomucoid in patients undergoing cardiac surgery: A promising novel inflammatory marker.
Kustán P; Szirmay B; Kőszegi T; Ludány A; Kovács GL; Miseta A; Mühl D; Németh B; Kiss I; Németh Á; Szabados S; Ajtay Z
Clin Biochem; 2017 Dec; 50(18):1002-1006. PubMed ID: 28736055
[TBL] [Abstract][Full Text] [Related]
5. Elevated urinary orosomucoid excretion as a novel biomarker in Crohn's disease.
Szirmay B; Tárnok A; Sarlós P; Szigeti N; Ludány A; Kustán P; Horváth-Szalai Z; Miseta A; Kőszegi T
Eur J Clin Invest; 2019 Mar; 49(3):e13054. PubMed ID: 30451301
[TBL] [Abstract][Full Text] [Related]
6. Urinary orosomucoid: a novel, early biomarker of sepsis with promising diagnostic performance.
Kustán P; Szirmay B; Horváth-Szalai Z; Ludány A; Kovács GL; Miseta A; Kőszegi T; Mühl D
Clin Chem Lab Med; 2017 Feb; 55(2):299-307. PubMed ID: 27816958
[TBL] [Abstract][Full Text] [Related]
7. Urinary orosomucoid: validation of an automated immune turbidimetric test and its possible clinical use.
Kustán P; Szirmay B; Horváth-Szalai Z; Ludány A; Lakatos Á; Mühl D; Christensen PH; Miseta A; Kovács GL; Kőszegi T
Biochem Med (Zagreb); 2016 Oct; 26(3):421-430. PubMed ID: 27812309
[TBL] [Abstract][Full Text] [Related]
8. Urinary Orosomucoid - 2 and Soluble CD14 as Potential Biomarkers for Assessment of Disease Activity in Rheumatoid Arthritis.
Sabry R; El-Madbouly AA; Abozeid HE; Hassan MM
Egypt J Immunol; 2018 Jun; 25(2):107-116. PubMed ID: 30600953
[TBL] [Abstract][Full Text] [Related]
9. Association between orosomucoid (ORM) types and psoriasis.
Fan C; Lidén S
Hum Hered; 1994; 44(2):72-6. PubMed ID: 8188313
[TBL] [Abstract][Full Text] [Related]
10. Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease.
Fandiño-Vaquero R; Fernández-Trasancos A; Alvarez E; Ahmad S; Batista-Oliveira AL; Adrio B; Fernández AL; González-Juanatey JR; Eiras S
Atherosclerosis; 2014 Aug; 235(2):281-8. PubMed ID: 24905138
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
12. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis as a cardiovascular risk factor: updates and algorithmic approach.
Cozzani E; Rosa GM; Burlando M; Parodi A
G Ital Dermatol Venereol; 2018 Oct; 153(5):659-665. PubMed ID: 29683293
[TBL] [Abstract][Full Text] [Related]
14. Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report.
Fan JM; Solomon DA; López GY; Hofmann JW; Colorado RA; Kim AS; Meisel K; Halabi C
BMC Neurol; 2020 Mar; 20(1):106. PubMed ID: 32199449
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.
Horreau C; Pouplard C; Brenaut E; Barnetche T; Misery L; Cribier B; Jullien D; Aractingi S; Aubin F; Joly P; Le Maître M; Ortonne JP; Paul C; Richard MA
J Eur Acad Dermatol Venereol; 2013 Aug; 27 Suppl 3():12-29. PubMed ID: 23845149
[TBL] [Abstract][Full Text] [Related]
16. Role of acute-phase protein ORM in a mice model of ischemic stroke.
Wan JJ; Wang PY; Zhang Y; Qin Z; Sun Y; Hu BH; Su DF; Xu DP; Liu X
J Cell Physiol; 2019 Nov; 234(11):20533-20545. PubMed ID: 31026065
[TBL] [Abstract][Full Text] [Related]
17. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
[TBL] [Abstract][Full Text] [Related]
18. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
19. Differential behaviour of epicardial adipose tissue-secretomes with high and low orosomucoid levels from patients with cardiovascular disease in H9C2 cells.
Lage R; Moscoso I; Fernández-Trasancos Á; Cebro M; Couselo M; Fandiño-Vaquero R; Bravo SB; Sierra J; González-Juanatey JR; Eiras S
Mol Cell Endocrinol; 2015 Nov; 416():77-87. PubMed ID: 26343163
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.
Ahlehoff O; Gislason GH; Charlot M; Jørgensen CH; Lindhardsen J; Olesen JB; Abildstrøm SZ; Skov L; Torp-Pedersen C; Hansen PR
J Intern Med; 2011 Aug; 270(2):147-57. PubMed ID: 21114692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
